Search

Your search keyword '"Benfante, Alida"' showing total 250 results
Start Over Author "Benfante, Alida" Search Limiters Academic (Peer-Reviewed) Journals
250 results on '"Benfante, Alida"'

2. Long-Term Clinical and Sustained REMIssion in Severe Eosinophilic Asthma Treated With Mepolizumab: The REMI-M Study

Author

Intravaia, Rossella, Porto, Morena, Impellizzeri, Pietro, Frazzetto, Valentina, Bonsignore, Martina, Giannì, Concetta, Nardo, Andrea Alessia, Vignera, Fabio, Busceti, Maria Teresa, Lombardo, Nicola, Lacedonia, Donato, Tondo, Pasquale, Soccio, Piera, Quarato, Carla Maria Irene, Montagnolo, Francesca, Salerno, Vittorio, Maselli, Leonardo, Julai, Ernesto, Coppa, Francesco, Grimaldi, Lucia, Carrieri, Isabella, Sola, Alessio, Balestrino, Marco, Mariniello, Domenica Francesca, Benfante, Alida, Spadaro, Giuseppe, Detoraki, Aikaterini, Ricciardi, Luisa, Antonio, Franzese, Valeria, Longobardi, Crimi, Claudia, Nolasco, Santi, Noto, Alberto, Maglio, Angelantonio, Quaranta, Vitaliano Nicola, Di Bona, Danilo, Scioscia, Giulia, Papia, Francesco, Caiaffa, Maria Filomena, Calabrese, Cecilia, D’Amato, Maria, Pelaia, Corrado, Campisi, Raffaele, Vitale, Carolina, Ciampo, Luigi, Dragonieri, Silvano, Minenna, Elena, Massaro, Federica, Gallotti, Lorena, Macchia, Luigi, Triggiani, Massimo, Scichilone, Nicola, Valenti, Giuseppe, Pelaia, Girolamo, Foschino Barbaro, Maria Pia, Carpagnano, Giovanna Elisiana, Vatrella, Alessandro, and Crimi, Nunzio

Published
2024
Full Text
View/download PDF

4. Are nighttime respiratory symptoms assessed by asthma control test affected by comorbidities?

Author

Benfante, Alida, Tomasello, Alessandra, Caponetto, Chiara, Battaglia, Salvatore, and Scichilone, Nicola

Subjects
*SLEEP quality, *SLEEP interruptions, *RHINITIS, *ASTHMA, *SLEEP disorders
Abstract

Objective: Nocturnal symptoms are common in the asthmatic population, reflecting an exaggerated airway narrowing overnight due to several factors; it is questioned to what extent the awakenings documented in the clinical assessment of asthma control are due to the disease itself or to comorbidities. To answer this question, we aimed to evaluate to what proportion rhinitis, gastroesophageal reflux and the likelihood of being affected by OSAS were related to poor asthma control, by means of ACT evaluation. Methods: Asthmatics attending the outpatient clinic were enrolled and administered the following questionnaires: ACT, Total 5 Symptom Score, GERD Impact Scale, Pittsburgh Sleep Quality Index and the Sleep Disorders Questionnaire. Results: One-hundred consecutive patients (M/F: 42/58, mean age 52 ± 15 years) were recruited. According to the ACT findings, 14 asthmatics resulted as fully controlled (FC, ACT equal to 25), 55 partially controlled (PC, 25 < ACT >19) and 31 as uncontrolled (UC, ACT <19). GERD was not associated with the ACT score neither did rhinitic symptomatology. On the other hand, the PSQI scores appeared to significantly increase with the lack of symptom control: FC, 2.0 (1–4); PC, 3.5 (2–5); UC, 6.6 (4–8) (p = 0.002). The SA-SDQ questionnaire results significantly increased with the loss of asthma control: FC, 11.0 (9–12); PC, 12.5 (10–14); UC, 15.1 (14–16) (p = 0.005). Conclusions: These results confirm and extend previous findings showing that there is a higher likelihood that underlying unknown sleep disturbances worsen asthma control, suggesting that a more comprehensive assessment is necessary to clarify the cause of nocturnal symptoms in asthma. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

6. Benralizumab Effectiveness in Severe Eosinophilic Asthma with and without Chronic Rhinosinusitis with Nasal Polyps: A Real-World Multicenter Study

Author

Nolasco, Santi, Crimi, Claudia, Pelaia, Corrado, Benfante, Alida, Caiaffa, Maria Filomena, Calabrese, Cecilia, Carpagnano, Giovanna Elisiana, Ciotta, Domenico, D'Amato, Maria, Macchia, Luigi, Pelaia, Girolamo, Pellegrino, Simona, Scichilone, Nicola, Scioscia, Giulia, Spadaro, Giuseppe, Campisi, Raffaele, Valenti, Giuseppe, Vatrella, Alessandro, and Crimi, Nunzio

Published
2021
Full Text
View/download PDF

7. Relevance of individual bronchial symptoms for asthma diagnosis and control in patients with rhinitis:A MASK-air study

Author

Sousa-Pinto, Bernardo, Louis, Gilles, Vieira, Rafael J., Czarlewski, Wienczyslawa, Anto, Josep M., Amaral, Rita, Sá-Sousa, Ana, Brussino, Luisa, Canonica, G. Walter, Loureiro, Claudia Chaves, Cruz, Alvaro A., Gemicioglu, Bilun, Haahtela, Tari, Kupczyk, Maciej, Kvedariene, Violeta, Larenas-Linnemann, Desirée E., Pham-Thi, Nhân, Puggioni, Francesca, Regateiro, Frederico S., Romantowski, Jan, Sastre, Joaquin, Scichilone, Nicola, Taborda-Barata, Luis, Ventura, Maria Teresa, Agache, Ioana, Bedbrook, Anna, Benfante, Alida, Bergmann, Karl C., Bosnic-Anticevich, Sinthia, Bonini, Matteo, Boulet, Louis Philippe, Brusselle, Guy, Buhl, Roland, Cecchi, Lorenzo, Charpin, Denis, Costa, Elisio M., Del Giacco, Stefano, Jutel, Marek, Klimek, Ludger, Kuna, Piotr, Laune, Daniel, Makela, Mika, Morais-Almeida, Mario, Nadif, Rachel, Niedoszytko, Marek, Papadopoulos, Nikolaos G., Papi, Alberto, Pfaar, Oliver, Rivero-Yeverino, Daniela, Ulrik, Charlotte Suppli, Sousa-Pinto, Bernardo, Louis, Gilles, Vieira, Rafael J., Czarlewski, Wienczyslawa, Anto, Josep M., Amaral, Rita, Sá-Sousa, Ana, Brussino, Luisa, Canonica, G. Walter, Loureiro, Claudia Chaves, Cruz, Alvaro A., Gemicioglu, Bilun, Haahtela, Tari, Kupczyk, Maciej, Kvedariene, Violeta, Larenas-Linnemann, Desirée E., Pham-Thi, Nhân, Puggioni, Francesca, Regateiro, Frederico S., Romantowski, Jan, Sastre, Joaquin, Scichilone, Nicola, Taborda-Barata, Luis, Ventura, Maria Teresa, Agache, Ioana, Bedbrook, Anna, Benfante, Alida, Bergmann, Karl C., Bosnic-Anticevich, Sinthia, Bonini, Matteo, Boulet, Louis Philippe, Brusselle, Guy, Buhl, Roland, Cecchi, Lorenzo, Charpin, Denis, Costa, Elisio M., Del Giacco, Stefano, Jutel, Marek, Klimek, Ludger, Kuna, Piotr, Laune, Daniel, Makela, Mika, Morais-Almeida, Mario, Nadif, Rachel, Niedoszytko, Marek, Papadopoulos, Nikolaos G., Papi, Alberto, Pfaar, Oliver, Rivero-Yeverino, Daniela, and Ulrik, Charlotte Suppli

Abstract

Rationale It is unclear how each individual asthma symptom is associated with asthma diagnosis or control. Objectives To assess the performance of individual asthma symptoms in the identification of patients with asthma and their association with asthma control. Methods In this cross-sectional study, we assessed real-world data using the MASK-air® app. We compared the frequency of occurrence of five asthma symptoms (dyspnea, wheezing, chest tightness, fatigue and night symptoms, as assessed by the Control of Allergic Rhinitis and Asthma Test [CARAT] questionnaire) in patients with probable, possible or no current asthma. We calculated the sensitivity, specificity and predictive values of each symptom, and assessed the association between each symptom and asthma control (measured using the e-DASTHMA score). Results were validated in a sample of patients with a physician-established diagnosis of asthma. Measurement and Main Results We included 951 patients (2153 CARAT assessments), with 468 having probable asthma, 166 possible asthma and 317 no evidence of asthma. Wheezing displayed the highest specificity (90.5%) and positive predictive value (90.8%). In patients with probable asthma, dyspnea and chest tightness were more strongly associated with asthma control than other symptoms. Dyspnea was the symptom with the highest sensitivity (76.1%) and the one consistently associated with the control of asthma as assessed by e-DASTHMA. Consistent results were observed when assessing patients with a physician-made diagnosis of asthma. Conclusions Wheezing and chest tightness were the asthma symptoms with the highest specificity for asthma diagnosis, while dyspnea displayed the highest sensitivity and strongest association with asthma control., Rationale: It is unclear how each individual asthma symptom is associated with asthma diagnosis or control. Objectives: To assess the performance of individual asthma symptoms in the identification of patients with asthma and their association with asthma control. Methods: In this cross-sectional study, we assessed real-world data using the MASK-air® app. We compared the frequency of occurrence of five asthma symptoms (dyspnea, wheezing, chest tightness, fatigue and night symptoms, as assessed by the Control of Allergic Rhinitis and Asthma Test [CARAT] questionnaire) in patients with probable, possible or no current asthma. We calculated the sensitivity, specificity and predictive values of each symptom, and assessed the association between each symptom and asthma control (measured using the e-DASTHMA score). Results were validated in a sample of patients with a physician-established diagnosis of asthma. Measurement and Main Results: We included 951 patients (2153 CARAT assessments), with 468 having probable asthma, 166 possible asthma and 317 no evidence of asthma. Wheezing displayed the highest specificity (90.5%) and positive predictive value (90.8%). In patients with probable asthma, dyspnea and chest tightness were more strongly associated with asthma control than other symptoms. Dyspnea was the symptom with the highest sensitivity (76.1%) and the one consistently associated with the control of asthma as assessed by e-DASTHMA. Consistent results were observed when assessing patients with a physician-made diagnosis of asthma. Conclusions: Wheezing and chest tightness were the asthma symptoms with the highest specificity for asthma diagnosis, while dyspnea displayed the highest sensitivity and strongest association with asthma control.

Published
2024

9. Real-world effectiveness and characteristics of Super-Responders to Mepolizumab and Benralizumab in severe eosinophilic asthma and EGPA

Author

Portacci, Andrea, primary, Campisi, Raffaele, additional, Buonamico, Enrico, additional, Nolasco, Santi, additional, Pelaia, Corrado, additional, Crimi, Nunzio, additional, Benfante, Alida, additional, Triggiani, Massimo, additional, Spadaro, Giuseppe, additional, Caiaffa, Maria Filomena, additional, Scioscia, Giulia, additional, Detoraki, Aikaterini, additional, Valenti, Giuseppe, additional, Papia, Francesco, additional, Tomasello, Alessandra, additional, Scichilone, Nicola, additional, Pelaia, Girolamo, additional, Crimi, Claudia, additional, and Carpagnano, Giovanna Elisiana, additional

Published
2023
Full Text
View/download PDF

10. Real-life effects of dupilumab in patients with severe type 2 asthma, according to atopic trait and presence of chronic rhinosinusitis with nasal polyps

Author

Pelaia, Corrado, primary, Benfante, Alida, additional, Busceti, Maria Teresa, additional, Caiaffa, Maria Filomena, additional, Campisi, Raffaele, additional, Carpagnano, Giovanna Elisiana, additional, Crimi, Nunzio, additional, D’Amato, Maria, additional, Foschino Barbaro, Maria Pia, additional, Maglio, Angelantonio, additional, Minenna, Elena, additional, Nolasco, Santi, additional, Paglino, Giuseppe, additional, Papia, Francesco, additional, Pelaia, Girolamo, additional, Portacci, Andrea, additional, Ricciardi, Luisa, additional, Scichilone, Nicola, additional, Scioscia, Giulia, additional, Triggiani, Massimo, additional, Valenti, Giuseppe, additional, Vatrella, Alessandro, additional, and Crimi, Claudia, additional

Published
2023
Full Text
View/download PDF

11. Radiomic features analysis to automatically predict COVID-19 severity outcome by using the LungQuant segmentation software: a multi-center study

Author

Scapicchio, Camilla, primary, Ballante, Elena, primary, Benfante, Alida, primary, Berta, Luca, primary, Bortolotto, Chandra, primary, Brero, Francesca, primary, Fiamma Cabini, Raffaella, primary, Chincarini, Andrea, primary, Cicolari, Davide, primary, Enrica Colombo, Paola, primary, Claudio Fanni, Salvatore, primary, Evelina Fantacci, Maria, primary, Figini, Silvia, primary, Grassedonio, Emanuele, primary, La Fiura, Andrea, primary, Lascialfari, Alessandro, primary, Lenardi, Cristina, primary, Lionetti, Alice, primary, Lizzi, Francesca, primary, Marrale, Maurizio, primary, Nardi, Cosimo, primary, Neri, Emanuele, primary, Postuma, Ian, primary, Preda, Lorenzo, primary, Rizzetto, Francesco, primary, Scichilone, Nicola, primary, Spina, Nicola, primary, talamonti, cinzia, primary, Torresin, Alberto, primary, Ubaldi, Leonardo, primary, Vanzulli, Angelo, primary, Zorzi, Giulia, primary, and Retico, Alessandra, primary

Published
2023
Full Text
View/download PDF

12. Real-world characteristics of “super-responders” to mepolizumab and benralizumab in severe eosinophilic asthma and eosinophilic granulomatosis with polyangiitis

Author

Portacci, Andrea, primary, Campisi, Raffaele, additional, Buonamico, Enrico, additional, Nolasco, Santi, additional, Pelaia, Corrado, additional, Crimi, Nunzio, additional, Benfante, Alida, additional, Triggiani, Massimo, additional, Spadaro, Giuseppe, additional, Caiaffa, Maria Filomena, additional, Scioscia, Giulia, additional, Detoraki, Aikaterini, additional, Valenti, Giuseppe, additional, Papia, Francesco, additional, Tomasello, Alessandra, additional, Scichilone, Nicola, additional, Pelaia, Girolamo, additional, Crimi, Claudia, additional, and Carpagnano, Giovanna Elisiana, additional

Published
2023
Full Text
View/download PDF

15. Effectiveness and safety of anti-IL-5/Rα biologics in eosinophilic granulomatosis with polyangiitis: a two-year multicenter observational study

Author

Nolasco, Santi, primary, Portacci, Andrea, additional, Campisi, Raffaele, additional, Buonamico, Enrico, additional, Pelaia, Corrado, additional, Benfante, Alida, additional, Triggiani, Massimo, additional, Spadaro, Giuseppe, additional, Caiaffa, Maria Filomena, additional, Scioscia, Giulia, additional, Detoraki, Aikaterini, additional, Valenti, Giuseppe, additional, Papia, Francesco, additional, Tomasello, Alessandra, additional, Crimi, Nunzio, additional, Scichilone, Nicola, additional, Pelaia, Girolamo, additional, Carpagnano, Giovanna Elisiana, additional, and Crimi, Claudia, additional

Published
2023
Full Text
View/download PDF

17. Asthma management in a specialist setting: Results of an Italian Respiratory Society survey

Author

Braido, Fulvio, Baiardini, Ilaria, Alleri, Pietro, Bacci, Elena, Barbetta, Carlo, Bellocchia, Michela, Benfante, Alida, Blasi, Francesco, Bucca, Caterina, Busceti, Maria Teresa, Centanni, Stefano, Colanardi, Maria Cristina, Contoli, Marco, Corsico, Angelo, D'Amato, Maria, Di Marco, Fabiano, Marco, Dottorini, Ferrari, Marta, Florio, Giovanni, Fois, Alessandro Giuseppe, Foschino Barbaro, Maria Pia, Silvia, Garuti, Girbino, Giuseppe, Grosso, Amelia, Latorre, Manuela, Maniscalco, Sara, Mazza, Francesco, Mereu, Carlo, Molinengo, Giorgia, Ora, Josuel, Paggiaro, Pierluigi, Patella, Vincenzo, Pelaia, Girolamo, Pirina, Pietro, Proietto, Alfio, Rogliani, Paola, Santus, Pierachille, Scichilone, Nicola, Simioli, Francesca, Solidoro, Paolo, Terraneo, Silvia, Zuccon, Umberto, and Canonica, Giorgio Walter

Published
2017
Full Text
View/download PDF

18. Impact of Actively Offering Influenza Vaccination to Frail People during Hospitalisation: A Pilot Study in Italy.

Author

Fallucca, Alessandra, Ferro, Patrizia, Mazzeo, Luca, Zagra, Luigi, Cocciola, Elena, Oliveri, Roberta, Tuttolomondo, Antonino, Benfante, Alida, Battaglia, Salvatore, Scichilone, Nicola, Veronese, Nicola, Affronti, Marco, Barbagallo, Mario, Casuccio, Alessandra, Vitale, Francesco, and Restivo, Vincenzo

Subjects
INFLUENZA vaccines, VACCINATION coverage, HOSPITAL care, PILOT projects
Abstract

Despite the worldwide recommendations for influenza immunisation, vaccination coverage for patients exposed to the highest risk of severe complications is still far from the optimal target. The need to take advantage of alternative methods to provide vaccination is essential. This study presents a hospital-based strategy which offers influenza vaccination to inpatients at discharge. This study was conducted during the 2022–2023 influenza season at the University Hospital of Palermo. A questionnaire was administered to identify the determinants for the acceptance of influenza vaccination in the frail population. Overall, 248 hospitalised patients were enrolled, of which 56.1% were female and 52.0% were over 65 years of age. The proportion of patients vaccinated against influenza during hospitalisation was 62.5%, an increase of 16% in influenza vaccination uptake among frail people in comparison with the previous influenza season (46.8% vaccinated during the 2021–22 influenza season). Factors significantly associated with vaccination acceptance were the following: to have received influenza vaccine advice from hospital healthcare workers (OR = 3.57, p = 0.001), to have been previously vaccinated for influenza (OR = 3.16 p = 0.005), and to have had a low level of education (OR = 3.56, p = 0.014). This study showed that offering influenza vaccination to hospitalised patients could be an effective strategy to increase vaccination coverage in the most vulnerable population, and these findings could be useful for planning and improving future influenza vaccination campaigns. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

21. Real-life effects of dupilumab in patients with severe type 2 asthma, according to atopic trait and presence of chronic rhinosinusitis with nasal polyps

Author

Pelaia, Corrado, Benfante, Alida, Busceti, Maria Teresa, Caiaffa, Maria Filomena, Campisi, Raffaele, Carpagnano, Giovanna Elisiana, Crimi, Nunzio, D’Amato, Maria, Foschino Barbaro, Maria Pia, Maglio, Angelantonio, Minenna, Elena, Nolasco, Santi, Paglino, Giuseppe, Papia, Francesco, Pelaia, Girolamo, Portacci, Andrea, Ricciardi, Luisa, Scichilone, Nicola, Scioscia, Giulia, Triggiani, Massimo, Valenti, Giuseppe, Vatrella, Alessandro, and Crimi, Claudia

Subjects
Immunology, Immunology and Allergy
Abstract

BackgroundThe efficacy of dupilumab as biological treatment of severe asthma and chronic rhinosinusitis with nasal polyps (CRSwNP) depends on its ability to inhibit the pathophysiologic mechanisms involved in type 2 inflammation.ObjectiveTo assess in a large sample of subjects with severe asthma, the therapeutic impact of dupilumab in real-life, with regard to positive or negative skin prick test (SPT) and CRSwNP presence or absence.MethodsClinical, functional, and laboratory parameters were measured at baseline and 24 weeks after the first dupilumab administration. Moreover, a comparative evaluation was carried out in relation to the presence or absence of SPT positivity and CRSwNP.ResultsAmong the 127 recruited patients with severe asthma, 90 had positive SPT, while 78 reported CRSwNP. Compared with the 6 months preceding the first dupilumab injection, asthma exacerbations decreased from 4.0 (2.0-5.0) to 0.0 (0.0-0.0) (p < 0.0001), as well as the daily prednisone intake fell from 12.50 mg (0.00-25.00) to 0.00 mg (0.00-0.00) (p < 0.0001). In the same period, asthma control test (ACT) score increased from 14 (10-18) to 22 (20-24) (p < 0.0001), and sino-nasal outcome test (SNOT-22) score dropped from 55.84 ± 20.32 to 19.76 ± 12.76 (p < 0.0001). Moreover, we observed relevant increases in forced expiratory volume in one second (FEV1) from the baseline value of 2.13 L (1.62-2.81) to 2.39 L (1.89-3.06) (p < 0.0001). Fractional exhaled nitric oxide (FeNO) values decreased from 27.0 ppb (18.0-37.5) to 13.0 ppb (5.0-20.0) (p < 0.0001). These improvements were quite similar in subgroups of patients characterized by SPT negativity or positivity, and CRSwNP absence or presence. No statistically significant correlations were detected between serum IgE levels, baseline blood eosinophils or FeNO levels and dupilumab-induced changes, with the exception of FEV1 increase, which was shown to be positively correlated with FeNO values (r = 0.3147; p < 0.01).ConclusionOur results consolidate the strategic position of dupilumab in its role as an excellent therapeutic option currently available within the context of modern biological treatments of severe asthma and CRSwNP, frequently driven by type 2 airway inflammation.

Published
2023

22. Echocardiographic Evaluation of the Cardiac Chambers in Asthmatic Patients: The BADA (Blood Pressure Levels, Clinical Features and Markers of Subclinical Cardiovascular Damage of Asthma Patients) Study-ECO

Author

Di Raimondo, Domenico, primary, Musiari, Gaia, additional, Rizzo, Giuliana, additional, Pirera, Edoardo, additional, Benfante, Alida, additional, Battaglia, Salvatore, additional, Colomba, Daniela, additional, Tuttolomondo, Antonino, additional, Scichilone, Nicola, additional, and Pinto, Antonio, additional

Published
2022
Full Text
View/download PDF

33. Effectiveness of benralizumab in severe eosinophilic asthma: Distinct sub‐phenotypes of response identified by cluster analysis

Author

Di Bona, Danilo, primary, Crimi, Claudia, additional, D’Uggento, Angela Maria, additional, Benfante, Alida, additional, Caiaffa, Maria Filomena, additional, Calabrese, Cecilia, additional, Campisi, Raffaele, additional, Carpagnano, Giovanna Elisiana, additional, Ciotta, Domenico, additional, D'Amato, Maria, additional, Pelaia, Corrado, additional, Pelaia, Girolamo, additional, Pellegrino, Simona, additional, Scichilone, Nicola, additional, Scioscia, Giulia, additional, Ribecco, Nunziata, additional, Spadaro, Giuseppe, additional, Valenti, Giuseppe, additional, Vatrella, Alessandro, additional, Crimi, Nunzio, additional, and Macchia, Luigi, additional

Published
2021
Full Text
View/download PDF

35. Applicability of the MASK-Air ® App to Severe Asthma Treated with Biologic Molecules: A Pilot Study.

Author

Benfante, Alida, Sousa-Pinto, Bernardo, Pillitteri, Gianluca, Battaglia, Salvatore, Fonseca, Joao, Bousquet, Jean, and Scichilone, Nicola

Subjects
*PATIENT compliance, *ASTHMATICS, *METERED-dose inhalers, *DYSPNEA, *VISUAL analog scale, *ASTHMA, *INHALERS
Abstract

MASK-air®, a good practice of the DG Santé, has been fully validated in allergic rhinitis, but little is known about its applicability to asthmatics. We explored whether the MASK-air® application is applicable to patients with severe asthma. Severe asthmatics were proposed to use the MASK-air® application for 6 months, along with best practice treatment. Treatment of the patients was not changed based on the application results. The evolution of the visual analogue scales (VAS) for asthma, shortness of breath, rhinitis, conjunctivitis, work, and sleep was monitored using MASK-air®. Adherence to MASK-air® and to the asthma treatment was also checked. Thirteen patients reported on 1229 days of MASK-air® use. The average application adherence was 51.8% (range: 19.7–98.9%). There was no correlation between application and medication adherence. Highly variably trends were found for the VAS for asthma. Five patients had over 90% well-controlled days, four had well- or moderately controlled asthma (with up to 20% uncontrolled days), one patient had moderately controlled asthma with approximately 20% uncontrolled days, and one patient had 80% uncontrolled days. Highly significant correlations were found for the VAS for asthma, and other patients reported VASs for work, dyspnea, sleep, and rhinitis. MASK-air® can be used in patients with severe asthma. VAS asthma appears to be an interesting patient-reported outcome highly correlated with dyspnea and impacts on work. Adherence to the application was better than that for rhinitis, but it needs to be improved. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

37. Management of severe asthma during the first lockdown phase of SARS-CoV-2 pandemic: Tips for facing the second wave

Author

Benfante Alida, Principe Stefania, Seminara Gabriele, Cicero Maria Noemi, Incandela Maria, Scichilone Nicola, Durante Carmen, Benfante A., Principe S., Cicero M.N., Incandela M., Seminara G., Durante C., and Scichilone N.

Subjects
Pulmonary and Respiratory Medicine, COVID-19, Health-care management, Respiratory symptoms, Severe asthma, severe asthma, medicine.medical_specialty, Telemedicine, Coronavirus disease 2019 (COVID-19), Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Severe asthma, Settore MED/10 - Malattie Dell'Apparato Respiratorio, Phase (combat), Article, Pandemic, medicine, Asthmatic patient, Humans, Pharmacology (medical), Intensive care medicine, health-care management, Pandemics, business.industry, SARS-CoV-2, Biochemistry (medical), Patient contact, respiratory symptoms, COVID-19, Asthma, Communicable Disease Control, business
Abstract

SARS-CoV-2 pandemic has contributed to implement telemedicine, allowing clinicians to follow the patient remotely, therefore minimizing the risk of any exposure to positive COVID-19 patients. We summarize the approaches adopted to treat and monitor severe asthmatic patients during the lockdown phase of the pandemic. Our experience supports the strategy that every effort should be made to minimize patient contact with the health-care system, planning a pathway that allows patients to receive appropriate medical care and continue the biological therapies, thus preventing the loss of disease control and acute severe exacerbations.

Published
2021

38. Therapeutic Effects of Benralizumab Assessed in Patients with Severe Eosinophilic Asthma: Real-Life Evaluation Correlated with Allergic and Non-Allergic Phenotype Expression

Author

Pelaia,Corrado, Crimi,Claudia, Benfante,Alida, Caiaffa,Maria Filomena, Calabrese,Cecilia, Carpagnano,Giovanna Elisiana, Ciotta,Domenico, D'Amato,Maria, Macchia,Luigi, Nolasco,Santi, Pelaia,Girolamo, Pellegrino,Simona, Scichilone,Nicola, Scioscia,Giulia, Spadaro,Giuseppe, Valenti,Giuseppe, Vatrella,Alessandro, Crimi,Nunzio, Pelaia,Corrado, Crimi,Claudia, Benfante,Alida, Caiaffa,Maria Filomena, Calabrese,Cecilia, Carpagnano,Giovanna Elisiana, Ciotta,Domenico, D'Amato,Maria, Macchia,Luigi, Nolasco,Santi, Pelaia,Girolamo, Pellegrino,Simona, Scichilone,Nicola, Scioscia,Giulia, Spadaro,Giuseppe, Valenti,Giuseppe, Vatrella,Alessandro, and Crimi,Nunzio

Abstract

Corrado Pelaia,1 Claudia Crimi,2 Alida Benfante,3 Maria Filomena Caiaffa,4 Cecilia Calabrese,5 Giovanna Elisiana Carpagnano,6 Domenico Ciotta Jnr,7 Maria D’Amato,8 Luigi Macchia,9 Santi Nolasco,2 Girolamo Pelaia,1 Simona Pellegrino,7 Nicola Scichilone,3 Giulia Scioscia,10 Giuseppe Spadaro,11 Giuseppe Valenti,12 Alessandro Vatrella,7 Nunzio Crimi2 1Department of Health Sciences, University “Magna Graecia” of Catanzaro, Catanzaro, Italy; 2Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy; 3Department of Biomedicine and Internal and Specialistic Medicine, University of Palermo, Palermo, Italy; 4Allergology and Clinical Immunology Unit, University of Foggia, Foggia, Italy; 5Department of Translational Medical Sciences, University of Campania “Luigi Vanvitelli”, Foggia, Italy; 6Department of Basic Medical Sciences, Neuroscience and Sense Organs, Section of Respiratory Disease, University “Aldo Moro” of Bari, Bari, Italy; 7Department of Medicine, Surgery and Dentistry, University of Salerno, Salerno, Italy; 8Division of Pneumology, “V. Monaldi” University Hospital, Naples, Italy; 9Allergology and Clinical Immunology Unit, University “Aldo Moro” of Bari, Bari, Italy; 10Department of Medical and Surgical Sciences, Institute of Respiratory Diseases, University of Foggia, Foggia, Italy; 11Allergology and Immunology Unit, University “Federico II” of Naples, Naples, Italy; 12Allergology and Pulmonology Unit, Provincial Outpatient Center of Palermo, Palermo, ItalyCorrespondence: Corrado PelaiaDepartment of Health Sciences, University “Magna Graecia” of Catanzaro, Catanzaro, ItalyTel + 39 0961 3647007Email pelaia.corrado@gmail.comBackground: Benralizumab can be utilized as add-on biological treatment of severe eosinophilic asthma. However, so far only a few real-life studies have been published

Published
2021

39. Resolution of Chronic Eosinophilic Pneumonia during Treatment with Benralizumab in Patient with Peripheric Blood Eosinophilia

Author

Giuliano, Alessandra, primary, Mandreucci, Francesca, additional, Benfante, Alida, additional, Noemi Cicero, Maria, additional, Seminara, Gabriele, additional, Scichilone, Nicola, additional, Carroccio, Antonio, additional, Maria Bruno, Erica, additional, Castellucci, Daniele, additional, Chiavetta, Marta, additional, Compagnoni, Stella, additional, Monachino, Noemi, additional, Teresi, Giulia, additional, Martorana, Giuseppe, additional, and Maisano, Simonetta, additional

Published
2021
Full Text
View/download PDF

41. The hidden burden of severe asthma: from patient perspective to new opportunities for clinicians

Author

Scichilone, Nicola, Barnes, John, Battaglia, Salvatore, Benfante, Alida, Brown, Robert, Canonica, Giorgio Walter, Caramori, Gaetano, Cazzola, Mario, Centanni, Stefano, Cianferoni, Antonella, Corsico, Angelo, De Carlo, Giuseppe, Di Marco, Fabiano, Gaga, Mina, Hawrylowicz, Catherine, Heffler, Enrico, Matera, Maria Gabriella, Matucci, Andrea, Paggiaro, Pierluigi, Papi, Alberto, Popov, Todor, Rogliani, Paola, Santus, Pierachille, Solidoro, Paolo, Togias, Alkis, Boulet, Louis-Philippe, Scichilone, Nicola, Barnes, John, Battaglia, Salvatore, Benfante, Alida, Brown, Robert, Canonica, Giorgio Walter, Caramori, Gaetano, Cazzola, Mario, Centanni, Stefano, Cianferoni, Antonella, Corsico, Angelo, De Carlo, Giuseppe, Di Marco, Fabiano, Gaga, Mina, Hawrylowicz, Catherine, Heffler, Enrico, Matera, Maria Gabriella, Matucci, Andrea, Paggiaro, Pierluigi, Papi, Alberto, Popov, Todor, Rogliani, Paola, Santus, Pierachille, Solidoro, Paolo, Togias, Alkis, and Boulet, Louis-Philippe

Abstract

Severe asthma is an important topic in respiratory diseases, due to its high impact on morbidity and mortality as well as on health-care resources. The many challenges that still exist in the management of the most difficult-to-treat forms of the disease, and the acknowledgement of the existence of unexplored areas in the pathophysiological mechanisms and the therapeutic targets represent an opportunity to gather experts in the field with the immediate goals to summarize current understanding about the natural history of severe asthma and to identify gaps in knowledge and research opportunities, with the aim to contribute to improved medical care and health outcomes. This article is a consensus document from the “International Course on Severe Asthma” that took place in Palermo, Italy, on May 10–11, 2019. Emerging topics in severe asthma were addressed and discussed among experts, with special focus on patient’s needs and research opportunities, with the aim to highlight the unanswered questions in the diagnostic process and therapeutic approach.

Published
2020

43. Therapeutic Effects of Benralizumab Assessed in Patients with Severe Eosinophilic Asthma: Real-Life Evaluation Correlated with Allergic and Non-Allergic Phenotype Expression

Author

Pelaia, Corrado, primary, Crimi, Claudia, additional, Benfante, Alida, additional, Caiaffa, Maria Filomena, additional, Calabrese, Cecilia, additional, Carpagnano, Giovanna Elisiana, additional, Ciotta, Domenico, additional, D'Amato, Maria, additional, Macchia, Luigi, additional, Nolasco, Santi, additional, Pelaia, Girolamo, additional, Pellegrino, Simona, additional, Scichilone, Nicola, additional, Scioscia, Giulia, additional, Spadaro, Giuseppe, additional, Valenti, Giuseppe, additional, Vatrella, Alessandro, additional, and Crimi, Nunzio, additional

Published
2021
Full Text
View/download PDF

45. Fever and dyspnoea in a tracheostomised patient

Author

Arena, Cinzia, primary, Scaduto, Federica, additional, Principe, Stefania, additional, Benfante, Alida, additional, Messina, Riccardo, additional, La Sala, Alba, additional, Serafino Agrusa, Laura, additional, Martorana, Anna, additional, Cabibi, Daniela, additional, Solidoro, Paolo, additional, and Scichilone, Nicola, additional

Published
2020
Full Text
View/download PDF

48. The Hidden Burden of Severe Asthma: From Patient Perspective to New Opportunities for Clinicians

Author

Scichilone, Nicola, primary, Barnes, Peter John, additional, Battaglia, Salvatore, additional, Benfante, Alida, additional, Brown, Robert, additional, Canonica, Giorgio Walter, additional, Caramori, Gaetano, additional, Cazzola, Mario, additional, Centanni, Stefano, additional, Cianferoni, Antonella, additional, Corsico, Angelo, additional, De Carlo, Giuseppe, additional, Di Marco, Fabiano, additional, Gaga, Mina, additional, Hawrylowicz, Catherine, additional, Heffler, Enrico, additional, Matera, Maria Gabriella, additional, Matucci, Andrea, additional, Paggiaro, Pierluigi, additional, Papi, Alberto, additional, Popov, Todor, additional, Rogliani, Paola, additional, Santus, Pierachille, additional, Solidoro, Paolo, additional, Togias, Alkis, additional, and Boulet, Louis-Philippe, additional

Published
2020
Full Text
View/download PDF

49. Management of suspected COVID-19 patients in a low prevalence region

Author

Scichilone, Nicola, primary, Basile, Laura, additional, Battaglia, Salvatore, additional, Benfante, Alida, additional, Fonte, Roberto, additional, Gambino, Francesco, additional, Marino, Stefania, additional, Messina, Riccardo, additional, Poma, Sonia, additional, Principe, Stefania, additional, Salamone, Giovanni, additional, and Zammuto, Marta, additional

Published
2020
Full Text
View/download PDF

50. Severe asthma and COVID-19: lessons from the first wave.

Author

Patrucco, Filippo, Benfante, Alida, Villa, Elisa, Principe, Stefania, Scichilone, Nicola, and Solidoro, Paolo

Subjects
*CORONAVIRUS diseases, *COVID-19 pandemic, *ASTHMA, *COVID-19, *BIOLOGICALS, *SARS-CoV-2
Abstract

Severe asthma is considered a risk factor for SARS-Coronavirus 2 (SARS-CoV-2) infection but scientific evidences are lacking. we performed a literature search and review based on PubMed database national, international recommendations as well as papers on severe asthmatic patients and their management during SARS-CoV-2 pandemic. the majority of international recommendations, expert panels and editorials provide indications about management of severe asthmatic patients. No published studies evaluated the effects of biologic agents on severe asthmatic patients during SARS-CoV-2 pandemic. the relationship between SARS-CoV-2 and asthma is variable worldwide and severe asthmatic patients were seldom reported in published cohorts. International recommendations suggest maintaining asthma under control to limit exacerbations occurrence, by using all available treatment. The minimum steroid dosage effective to control symptoms should be maintained to avoid exacerbations; biologic agents administration should be regularly scheduled encouraging patient support programmes. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results